Australia: Generics win the battle for CRESTOR, but lose the war over inventive step

Last Updated: 25 August 2014

While the Full Court's decision represents a loss for AstraZeneca, it places innovators at a significant advantage over generic companies in respect of follow-on inventions (such as formulations and dosage regimes). Where an innovator is familiar with a particular compound the innovator will effectively have a "head-start" over other companies.

The Full Court's finding that the generics would have contravened the 'infringement by supply' provisions in s117 coupled with the Court's comments that it may not have been appropriate to grant an injunction raises further uncertainty about the operation of those provisions.

An enlarged Full Federal Court (Besanko, Jessup, Foster, Nicholas and Yates JJ) in AstraZeneca AB v Apotex Pty Ltd [2014] FCAFC 99 has upheld a decision by Justice Jagot finding that two AstraZeneca patents protecting the blockbuster product CRESTOR (rosuvastatin) were invalid. The patents where challenged by three generic pharmaceutical companies: Apotex, Watson and Ascent Pharma.

The key issue in the appeal was identifying the proper "starting point" for assessing inventive step and, in particular, whether the problem set out in a patent speciation necessarily forms part of the "common general knowledge". The Full Court overturned Justice Jagot's finding that knowledge of rosuvastatin can be taken as the "starting point" as the common general knowledge must be assessed objectively.

Nevertheless, in the present case the Full Court upheld the findings that the patents were invalid on other grounds. This article only addresses the Full Court's findings with respect to inventive step (Cation Patent), the priority date (Cation Patent), entitlement (Low Dose Patent) and novelty (Low Dose Patent).

This article also addresses the Full Court's findings with respect to allegations that the generics would infringe the Low Dose Patent by supplying 20mg and 40mg tablets with the knowledge they would be split. The Full Court held that, had the patent been valid, the generics would have infringed under s117 of the Act, which prohibits supplying a product with reason to believe it will be put to an infringing use or directions to put the product to such a use. The Court commented that, in circumstances where only a small proportion of use would be infringing it may not be appropriate to grant an injunction. This raises further questions about the operation of the provision and the Court's approach may be questioned on the basis that the Act deems the supply to be infringing.

STARTING POINT (CATION PATENT)

While the Court upheld Justice Jagot's finding that the Cation Patent was invalid, it overturned the key finding in relation to the proper "starting point" for assessing inventive step.

At first instance, Justice Jagot found that the statement of the problem, which pre-supposed knowledge of rosuvastatin, should be taken into account as part of the common general knowledge, otherwise the invention (which claims a pharmaceutical composition) would be transformed "into something which includes the discovery of rosuvastatin". Accordingly, Her Honour found that the starting point was the problem identified in the Cation Patent namely, how to create a composition with containing rosuvastatin with improved stability characteristics.

However, the Full Court found that the problem that is addressed in a patent specification does not necessarily form part of the "common general knowledge" against which inventive step is to be assessed. The Court cited the following key reasons in support of this conclusion.

  • It is not necessarily the case that the "starting point" outlined in the patent would have been apparent to the skilled person.
  • There is no requirement to describe the starting point in the specification.
  • Otherwise, information that was not public might be taken to form part of the common general knowledge which is contrary to the basic principles of patent law.

The Full Court's reasoning is persuasive. Otherwise a patent claiming an invention might lack inventive step where the inventor's understanding of the problem is disclosed, but be valid if the inventor did not describe the problem in the patent.

While the Full Court's approach favours consistency and objectivity, it may be seen to provide a "head-start" for innovators who have particular knowledge about a substance when compared to others in the field. Indeed, it will not always be apparent to those in the relevant field that there is a particular problem that needs to be overcome.

This finding places innovators at an advantage with respect to follow-on patents where the active compound has not yet been marketed. Follow-on patents, such as patents for formulations, which may have been "obvious" to those with knowledge of the compound in question are nevertheless likely to be valid when tested against the lower level of knowledge of other skilled persons in the field.

PRIORITY DATE (CATION PATENT)

In order to defeat the challenge to the validity of the Cation Patent, AstraZeneca also needed to persuade the Full Court to overturn Justice Jagot's finding that the priority date of the Cation Patent was in August 2000 rather than the date the patent was amended in January 2005. AstraZeneca accepted that if the priority date was January 2005 the Cation Patent lacked novelty.

The 2005 amendments excluded from the claims certain inorganic salts (where the counter anion is a phosphate). AstraZeneca argued that the effect of the amendments was to narrow the claims of the Cation Patent, with the result that the patent continued to enjoy the August 2000 priority date.

Justice Jagot found that the priority date was deferred to January 2005 because the amendments introduced a limitation on the claim (disclaiming compositions which used phosphate as the counter anion) which changed the nature of the invention.

The Full Court upheld this finding, holding that the patent before amendment did not disclose the invention (after amendment) because the patent before amendment positively recommended the use of the embodiment of the invention (i.e. counter anion is a phosphate) and this was excluded in 2005.

This finding reinforces the need to give careful consideration to the consequences of amending a patent as it demonstrates that even narrowing amendments can be problematic. Equally, it highlights the need for those challenging the validity of a patent to consider the file history, including the scope of any amendments, in detail.

ENTITLEMENT (LOW DOSE PATENT)

AstraZeneca acquired the rights to the compound rosuvastatin from the company responsible for its discovery, Shionogi & Co Ltd (Shionogi).

The generics argued that that the Low Dose Patent was invalid for lack of entitlement on the basis that the employees of Shionogi had contributed to the invention. Justice Jagot accepted this argument and the Full Court affirmed this finding.

AstraZeneca argued that while Shionogi had invented the compound rosuvastatin it had not proved a method of administration (i.e. dosage regimen). However, the Court found that Shionogi had conceived a method of administration and was entitled to the invention.

Further, the Full Court held that AstraZeneca could not rely on s22A and s138(4) of the Act which provide that a patent is not invalid merely because it is was not granted to the person entitled and limit the Court's discretion to revoke a patent for lack of entitlement to circumstances in which it is "just and equitable to do so". These provisions were introduced following Justice Jagot's decision and the Full Court found that its function was limited to reviewing Her Honour's decision.

Notwithstanding the introduction of s22A and s138(4) which clearly favour patentees in relation to this ground of invalidity, the Full Court's finding highlights the need for patentees to carefully consider all contributions to the invention before filing a patent application. In the case of follow-on inventions it is important to consider whether inventors of earlier related inventions have made a material contribution to the invention in question.

NOVELTY (LOW DOSE PATENT) – 471 PATENT AND WATANABE

Justice Jagot found that the Low Dose Patent was anticipated by an earlier patent (the 471 Patent) which disclosed a broad class of compounds with cholesterol lowering activity and a dosage regimen. The Full Court overturned this finding on the basis that while the 471 Patent disclosed a dosage range which was broad enough to include the regimen claimed in the Low Dose Patent, it did not specifically disclose the regimen (a starting dose of 5 to 10mg) claimed in the Low Dose Patent.

Justice Jagot also found that the Low Dose patent was anticipated by an article which reported on the synthesis and characteristics of a number of compounds including rosuvastatin (the Watanabe article). The Watanabe article discussed the activity of the compounds based on animal tests.

AstraZeneca argued that there was no disclosure of any dosage range in the Wantanabe article and Justice Jagot impermissibly took into account the common general knowledge regarding the potency of rosuvastatin and suitable dosage ranges. In this regard, Justice Jagot relied on evidence given by Professor O'Brien, an expert for the generics, in relation to inventive step.

The Full Court overturned Justice Jagot's finding on the basis that Her Honour used the common general knowledge to supplement the disclosure in the Watanabe article which did not itself (expressly or impliedly) disclose any dosage regimen for the use of the rosuvastatin in humans. The Court held that while the common general knowledge can be used to construe a prior art document for the purposes of assessing novelty it is impermissible to use the common general knowledge as a separate resource (as is permissible in the case of inventive step).

This aspect of the Court's decision highlights the need to ensure that novelty challenges are based on the understanding of prior art by a skilled addressee in light of their acquired knowledge but not using that knowledge to "fill gaps" in the prior art. As this case demonstrates, the distinction can be elusive.

INFRINGEMENT BY SUPPLY (LOW DOSE PATENT)

AstraZeneca argued that the supply of 20mg and 40mg dosages of rosuvastatin by the generics would infringe the Low Dose Patent under the 'infringement by supply' provisions in s117 of the Act. Under s117 a supply of a non-staple commercial product (rosuvastatin was found be such a product) will be an infringement where:

  1. the supplier had reason to believe it would be put to an infringing use (s117(2)(b)); or
  2. the supplier has provided instructions for the use of the product which would lead users to infringe (s117(2)(c)).

AstraZeneca argued that the generics were aware that consumers would engage in "tablet-splitting" and consequently follow the dosage regimen claimed in the Low Dose Patent.

At first instance Justice Jagot found that the generics would not infringe under s117 because there was insufficient evidence that the generics had reason to believe that consumers would engage in tablet splitting, though Her Honour accepted that there was a risk this may take place. In relation to Watson's product information, which acknowledged that tablets could be split, Her Honour did not consider that this amounted to a sufficient instruction that would "induce" consumers for the purpose of s117(2)(c).

The Full Court overturned Justice Jagot's findings in relation to s117. The Court held that, even though the proportion of consumers that would engage in tablet-splitting was likely to be small (only 2.75% of prescriptions were for "half a 20mg tablet"), the generics "had reason to believe" that at least some consumers would engage in that practice.

However, the Full Court cautioned that, when considering whether to grant an injunction, "some consideration of proportionality as between the extent of the infringing use that is forecast and the scope of any injunctive relief is warranted". The Court noted that, where only a small proportion of use is likely to be infringing, it should be more difficult to obtain an injunction. Similarly, the Full Court was satisfied that Watson's product information provided a relevant instruction for the purposes of s117(2)(c).

While the Full Court's comments are clearly motivated by a desire to achieve a "fair" and "proportionate" outcome, the approach may be challenged on the basis that the Act deems the supply to be infringing irrespective of the end use.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Most awarded firm and Australian deal of the year
Australasian Legal Business Awards
Employer of Choice for Women
Equal Opportunity for Women
in the Workplace (EOWA)

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions